Our Advisory Board.
Our Pharmacovigilance advisory board.
Dr. John Price, Dr. Judith M. Sills, Dr. Panos Tsintis and Dr. Eric Caugant head up Arriello’s Pharmacovigilance advisory board, bringing their extensive global experience to help shape and direct our future pharmacovigilance strategy and operations.
Based evenly across the US and Europe, each of our board members commands a unique high-level industry insight, having worked with or for the EMA, FDA, MHRA, ICH, CIOMS and many other key organizations on national and global projects and initiatives.
Our US team.
Dr. John Price
is an executive physician with deep experience gained from over 25 years working across the breadth of regulatory affairs and pharmacovigilance worldwide.
He has created and led high-functioning global departments for pharmacovigilance, regulatory and clinical operations, medical writing and drug development, and held senior roles in the UK Medicines Control Agency (now MHRA), Pfizer, J&J, Alexion Pharmaceuticals, and academia.
Dr. Judith M. Sills, Pharm.D.
is President of JM Sills Consulting LLC, specializing in pharmacovigilance and benefit-risk management.
Dr. Sills has over 30 years of experience in pharmacovigilance in the pharmaceutical industry, FDA, and consulting.
Prior to establishing a consulting practice in 2018, she was Vice President and Head, Global Pharmacovigilance at The Medicines Company.
Our EU team.
Dr. Panos Tsintis
has a total of over 20 years of pharmacovigilance, regulatory affairs and pharmaceutical medicine experience, from drug development to post-marketing.
Between 2002 and 2008 he was Head of Pharmacovigilance and Post-Authorisation Safety and Efficacy Sector at the European Medicines Agency (EMA).
He has also held senior positions at the UK MHRA as well as in the pharmaceutical industry.
Dr. Eric Caugant
has over 25 years of experience in Pharmacovigilance, Drug Safety, Risk Management, and more broadly Pharmaceutical Medicine.
In 2017, he founded Pharmacovigilance Systems Consulting (PhVSC).
Prior to this Eric held senior positions, in various pharmaceutical and biotech companies, such as Alexion, Bayer Lilly, Wyeth and also the French Ministry of Health.